Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy

Haruhito Adam Uchida, Yoshio Nakamura, Masanobu Kaihara, Hisanao Norii, Yoshihisa Hanayama, Hitoshi Sugiyama, Yohei Maeshima, Yasushi Yamasaki, Hirofumi Makino

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background. Decreased plasma adiponectin is associated with impaired endothelial function and, thereby, increased risk for cardiovascular events. Glucocorticoid (GC) affects vascular endothelial cells either favourably or harmfully depending upon the dosages and duration. We examined the effect of GC pulse therapy on vascular endothelial function. Methods. Fourteen young patients with IgA nephropathy were evaluated for flow-mediated vasodilation (FMD), plasma levels of adiponectin both in high molecular weight (HMW adiponectin) form and in single molecular form (total adiponectin), hepatocyte growth factor (HGF), asymmetric dimethylarginine (ADMA), and high-sensitive C-reactive protein, before and after a course of GC pulse therapy. Results. GC pulse therapy significantly decreased FMD (from 7.2 ± 2.6 to 5.7 ± 2.5%, P <0.01). Meanwhile, plasma adiponectin levels were significantly augmented (total adiponectin: from 10.2 ± 4.0 to 12.1 ± 6.3 μg/ml, P <0.05; HMW: from 6.5 ± 3.2 to 7.7 ± 3.3 μg/ml, P <0.05). In parallel, elevated concentrations of serum HGF (from 0.28 ± 0.12 to 0.63 ± 0.38 ng/ml, P <0.01) and plasma ADMA (from 0.45 ± 0.07 to 0.53 ± 0.04 nmol/ml, P <0.05) were observed. Conclusions. GC pulse therapy impaired endothelial function while increasing plasma adiponectin levels, which may in turn restore the endothelial function in patients with IgA nephropathy.

Original languageEnglish
Pages (from-to)3475-3480
Number of pages6
JournalNephrology Dialysis Transplantation
Volume21
Issue number12
DOIs
Publication statusPublished - Dec 1 2006

Fingerprint

Adiponectin
Immunoglobulin A
Steroids
Glucocorticoids
Hepatocyte Growth Factor
Vasodilation
Therapeutics
C-Reactive Protein
Blood Vessels
Endothelial Cells
Molecular Weight
Serum

Keywords

  • Asymmetric dimethylarginine
  • Endothelial dysfunction
  • Glucocorticoid
  • Hepatocyte growth factor
  • High molecular weight adiponectin
  • IgA nephropathy

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

@article{0bd2b69d9274437bb3a6c759ff371205,
title = "Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy",
abstract = "Background. Decreased plasma adiponectin is associated with impaired endothelial function and, thereby, increased risk for cardiovascular events. Glucocorticoid (GC) affects vascular endothelial cells either favourably or harmfully depending upon the dosages and duration. We examined the effect of GC pulse therapy on vascular endothelial function. Methods. Fourteen young patients with IgA nephropathy were evaluated for flow-mediated vasodilation (FMD), plasma levels of adiponectin both in high molecular weight (HMW adiponectin) form and in single molecular form (total adiponectin), hepatocyte growth factor (HGF), asymmetric dimethylarginine (ADMA), and high-sensitive C-reactive protein, before and after a course of GC pulse therapy. Results. GC pulse therapy significantly decreased FMD (from 7.2 ± 2.6 to 5.7 ± 2.5{\%}, P <0.01). Meanwhile, plasma adiponectin levels were significantly augmented (total adiponectin: from 10.2 ± 4.0 to 12.1 ± 6.3 μg/ml, P <0.05; HMW: from 6.5 ± 3.2 to 7.7 ± 3.3 μg/ml, P <0.05). In parallel, elevated concentrations of serum HGF (from 0.28 ± 0.12 to 0.63 ± 0.38 ng/ml, P <0.01) and plasma ADMA (from 0.45 ± 0.07 to 0.53 ± 0.04 nmol/ml, P <0.05) were observed. Conclusions. GC pulse therapy impaired endothelial function while increasing plasma adiponectin levels, which may in turn restore the endothelial function in patients with IgA nephropathy.",
keywords = "Asymmetric dimethylarginine, Endothelial dysfunction, Glucocorticoid, Hepatocyte growth factor, High molecular weight adiponectin, IgA nephropathy",
author = "Uchida, {Haruhito Adam} and Yoshio Nakamura and Masanobu Kaihara and Hisanao Norii and Yoshihisa Hanayama and Hitoshi Sugiyama and Yohei Maeshima and Yasushi Yamasaki and Hirofumi Makino",
year = "2006",
month = "12",
day = "1",
doi = "10.1093/ndt/gfl423",
language = "English",
volume = "21",
pages = "3475--3480",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy

AU - Uchida, Haruhito Adam

AU - Nakamura, Yoshio

AU - Kaihara, Masanobu

AU - Norii, Hisanao

AU - Hanayama, Yoshihisa

AU - Sugiyama, Hitoshi

AU - Maeshima, Yohei

AU - Yamasaki, Yasushi

AU - Makino, Hirofumi

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Background. Decreased plasma adiponectin is associated with impaired endothelial function and, thereby, increased risk for cardiovascular events. Glucocorticoid (GC) affects vascular endothelial cells either favourably or harmfully depending upon the dosages and duration. We examined the effect of GC pulse therapy on vascular endothelial function. Methods. Fourteen young patients with IgA nephropathy were evaluated for flow-mediated vasodilation (FMD), plasma levels of adiponectin both in high molecular weight (HMW adiponectin) form and in single molecular form (total adiponectin), hepatocyte growth factor (HGF), asymmetric dimethylarginine (ADMA), and high-sensitive C-reactive protein, before and after a course of GC pulse therapy. Results. GC pulse therapy significantly decreased FMD (from 7.2 ± 2.6 to 5.7 ± 2.5%, P <0.01). Meanwhile, plasma adiponectin levels were significantly augmented (total adiponectin: from 10.2 ± 4.0 to 12.1 ± 6.3 μg/ml, P <0.05; HMW: from 6.5 ± 3.2 to 7.7 ± 3.3 μg/ml, P <0.05). In parallel, elevated concentrations of serum HGF (from 0.28 ± 0.12 to 0.63 ± 0.38 ng/ml, P <0.01) and plasma ADMA (from 0.45 ± 0.07 to 0.53 ± 0.04 nmol/ml, P <0.05) were observed. Conclusions. GC pulse therapy impaired endothelial function while increasing plasma adiponectin levels, which may in turn restore the endothelial function in patients with IgA nephropathy.

AB - Background. Decreased plasma adiponectin is associated with impaired endothelial function and, thereby, increased risk for cardiovascular events. Glucocorticoid (GC) affects vascular endothelial cells either favourably or harmfully depending upon the dosages and duration. We examined the effect of GC pulse therapy on vascular endothelial function. Methods. Fourteen young patients with IgA nephropathy were evaluated for flow-mediated vasodilation (FMD), plasma levels of adiponectin both in high molecular weight (HMW adiponectin) form and in single molecular form (total adiponectin), hepatocyte growth factor (HGF), asymmetric dimethylarginine (ADMA), and high-sensitive C-reactive protein, before and after a course of GC pulse therapy. Results. GC pulse therapy significantly decreased FMD (from 7.2 ± 2.6 to 5.7 ± 2.5%, P <0.01). Meanwhile, plasma adiponectin levels were significantly augmented (total adiponectin: from 10.2 ± 4.0 to 12.1 ± 6.3 μg/ml, P <0.05; HMW: from 6.5 ± 3.2 to 7.7 ± 3.3 μg/ml, P <0.05). In parallel, elevated concentrations of serum HGF (from 0.28 ± 0.12 to 0.63 ± 0.38 ng/ml, P <0.01) and plasma ADMA (from 0.45 ± 0.07 to 0.53 ± 0.04 nmol/ml, P <0.05) were observed. Conclusions. GC pulse therapy impaired endothelial function while increasing plasma adiponectin levels, which may in turn restore the endothelial function in patients with IgA nephropathy.

KW - Asymmetric dimethylarginine

KW - Endothelial dysfunction

KW - Glucocorticoid

KW - Hepatocyte growth factor

KW - High molecular weight adiponectin

KW - IgA nephropathy

UR - http://www.scopus.com/inward/record.url?scp=33751406222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751406222&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfl423

DO - 10.1093/ndt/gfl423

M3 - Article

C2 - 16951422

AN - SCOPUS:33751406222

VL - 21

SP - 3475

EP - 3480

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 12

ER -